Article
Emerging Dealmaking Trends in Gene Therapy
IQVIA Pharma Deals
Sep 14, 2022

In recent years, gene therapy products and technologies have been one of the most prominent drivers in dealmaking within the life sciences sector, despite the multiple challenges faced in drug development and commercialization. The number of gene therapy deals signed is now at its highest level in 5 years, with 310 deals signed in 2021 compared to only 164 in 2017. With recent clinical and regulatory advances, deal activity is likely to remain strong as companies race to secure a position in this lucrative market.

Related solutions

Contact Us